Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

positive   publishing date : 2022 - 04 - 04    save search

Colts Make Serious Moves At Two Vitally Important Positions
Published: 2022-04-04 (Crawled : 17:00) - emmis.com
ARVL | News | $0.49 0.37% 2.5M twitter stocktwits trandingview |
Manufacturing
| | O: -2.36% H: 0.0% C: 0.0%

positive
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Published: 2022-04-04 (Crawled : 13:20) - globenewswire.com
TOMDF | $0.0001 100.0% 14M twitter stocktwits trandingview |
Manufacturing
| | O: 0.0% H: 20.61% C: 5.45%

sars-cov-2 positive in vitro
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
Published: 2022-04-04 (Crawled : 13:00) - biospace.com/
PHAS | $0.0701 -23.97% twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 9.92% C: -2.48%

trial bentracimab positive results phase 2b
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
WVE | $5.06 4.55% 180K twitter stocktwits trandingview |
Health Technology
| | O: 3.94% H: 35.07% C: 9.95%

wve-004 ongoing positive phase 2b
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
Published: 2022-04-04 (Crawled : 12:00) - globenewswire.com
INZY | $4.52 2.96% 470K twitter stocktwits trandingview |
Health Technology
| | O: 9.28% H: 8.01% C: 4.37%

inz-701 pharma trial positive phase 1
Yamana Gold Announces Positive Exploration Results Underpinning Strategic Upside at El Peñón, Odyssey and Wasamac, Announces Completion of TCFD Climate Action Report Relating to Recently Announced Climate Action Strategy, and Notes Investor Day on April 5
Published: 2022-04-04 (Crawled : 11:00) - globenewswire.com
AUY | $5.85 -0.68% -0.51% 0 twitter stocktwits trandingview |
Non-Energy Minerals
| | O: 0.35% H: 2.94% C: 2.76%

day report positive results
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Published: 2022-04-04 (Crawled : 05:00) - prnewswire.com
IONS | $42.07 2.44% 260K twitter stocktwits trandingview |
Health Technology
| | O: 0.1% H: 0.41% C: -0.54%

cardiology positive phase 2b
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M twitter stocktwits trandingview |

AGBA | $2.74 119.2% 52M twitter stocktwits trandingview |
Finance

CZOO | $9.07 81.76% 22M twitter stocktwits trandingview |

EDBL | News | $6.56 74.47% 1.8M twitter stocktwits trandingview |

MTC | $2.21 41.67% 5.6M twitter stocktwits trandingview |
Technology Services

OPRT | News | $3.12 38.67% 11M twitter stocktwits trandingview |
Finance

PALI | $6.59 33.67% 23M twitter stocktwits trandingview |
Manufacturing

VNRX | $0.7945 32.42% 3.1M twitter stocktwits trandingview |
Health Technology

MLEC | $1.81 29.29% 2.8M twitter stocktwits trandingview |
n/a

BTCM | $3.45 27.78% 640K twitter stocktwits trandingview |
Arts, Entertainment, and Recrea...


Your saved searches
Save your searches and get alerts when important news are released.